Table 5.

Multivariable models evaluating factors associated with levels of AST and ALT among TF and CF study participants

	AST		ALT
Parameter of interest	Difference (%)	95% CI	Difference (%)	95% CI
Gender identity (TF vs CF)	1	−5, 8	14	9, 19
Site (KPNC vs other)	4	1, 8	8	5, 11
Age group (y) vs 18–25
26–35	0	−5, 5	0	−4, 4
36–45	4	−1, 9	3	−1, 7
46–55	8	3, 15	11	6, 15
56+	21	14, 27	15	11, 20
Race/ethnicity (vs NHW)
Non-Hispanic Black	1	−5, 6	−11	−16, −8
Hispanic	8	4, 14	6	3, 11
Asian/Pacific Islander	1	−5, 7	0	−4, 4
Other/Unknown	0	−9, 9	2	−5, 8
Body mass index (kg/m2) ≥25.0 vs <25.0	3	−1, 6	22	20, 26
Alcohol use/abuse (yes vs no)	13	8, 17	13	8, 16
Time (10-d increments)
Pre-GAHT	2	−2, 5	−2	−5, 1
Post-GAHT	−4	−14, 6	1	−6, 8
Pre-GAHT × gender identity	−13	−24, 0	−27	−34, −17
Post-GAHT × gender identity	−2	−27, 34	0	−18, 23
Calculated adjusted average 10-d change (%)
TF pre-GAHT	−11	−22, 1	−29	−35, −20
TF post-GAHT	−16	−33, 5	−27	−36, −16
CF pre-GAHT	2	−2, 5	−2	−5, 1
CF post-GAHT	−2	−10, 6	−1	−6, 5
Ratio-of-ratios for 10-d change among TF (post- vs pre-GAHT)	0.94	0.71, 1.26	1.02	0.84, 1.23
Ratio-of-ratios for post-GAHT 10-d change (TF vs CF)	0.86	0.68, 1.09	0.74	0.64, 0.85

ALT = alanine aminotransferase; AST = aspartate aminotransferase; CI = confidence interval; CF = cisgender females; GAHT = gender affirming hormone therapy; KPNC = Kaiser Permanente Northern California; TF = transfeminine, NHW = non-Hispanic White.